Medicare Rx Formulary Reviews Will Be Largely Automated, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The automated process will account for approximately 75% of the Part D formulary review process, CMS Division of Finance & Operations-Medicare Drug Benefit Group Director Edgar says. “Outliers” identified by the automated process will then be reviewed by a clinical pharmacist, the agency rep says.